Table 1.

TPO and TGF-β1 levels in untreated and TPO-treated (days 7, 14, and 21 after receiving 100 μg TPO/kg of body weight/day for 5 consecutive days, as indicated) wild-type and GATA-1low mice

UntreatedDay 7Day 14Day 21
Wild typeGATA-1lowWild typeGATA-1lowWild typeGATA-1lowWild typeGATA-1low
TPO
   Plasma, ng/mL (no. of mice) 0.76 ± 0.12 (10) 0.75 ± 0.20 (8) 6.0 ± 0.5 (10) 5.7 ± 0.8 (8) 0.48 ± 0.15 (10) 0.54 ± 0.16 (8) 0.58 ± 0.12 (10) 0.65 ± 0.10 (8)
   P - NS < .001 < .001 NS NS NS NS
TGF-1β
   Plasma, ng/mL (no. of mice) 2.1 ± 0.4 (10) 1.8 ± 0.7 (8) 16.2 ± 2.7 (10) 3.5 ± 1.3 (8) 9.2 ± 2.0 (10) 2.2 ± 0.8 (8) 2.0 ± 1.0 (10) 2.0 ± 1.1 (8)
   P - NS < .01 NS < .01 NS NS NS
   Extracellular fluids
      Bone marrow, ng/mL (no. of mice) 0.86 ± 0.21 (5) 1.88 ± 0.33 (4) ND ND 3.45 ± 0.45 (5) 1.62 ± 0.60 (4) ND ND
      P - < .05 ND ND < .01 NS ND ND
      Spleen, ng/mL (no. of mice) 1.88 ± 0.39 (5) 3.20 ± 0.80 (4) ND ND 4.53 ± 1.20 (5) 3.55 ± 0.65 (4) ND ND
      P - < .01 ND ND < .01 ND ND ND
  • For statistical analysis, values observed in untreated GATA-1low mice were compared with those observed in untreated wild-type littermates, while values observed in treated animals were compared with those observed in the respective untreated controls.

    ND indicates not done; NS, not significantly different (P > .05) from controls; -, not applicable.